In the last trading session, 3.11 million BridgeBio Pharma Inc (NASDAQ:BBIO) shares changed hands as the company’s beta touched 1.09. With the company’s per share price at $32.98 changed hands at $1.95 or 6.28% during last session, the market valuation stood at $6.23B. BBIO’s last price was a discount, traded about -24.44% off its 52-week high of $41.04. The share price had its 52-week low at $21.62, which suggests the last value was 34.45% up since then. When we look at BridgeBio Pharma Inc’s average trading volume, we note the 10-day average is 2.65 million shares, with the 3-month average coming to 2.48 million.
Analysts gave the BridgeBio Pharma Inc (BBIO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.29. If we narrow down to specifics, the data shows that 0 out of 9 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended BBIO as a Hold, 9 felt it is a Buy and 0 rated the stock as Underweight. BridgeBio Pharma Inc’s EPS for the current quarter is expected to be -1.09.
BridgeBio Pharma Inc (NASDAQ:BBIO) trade information
Instantly BBIO was in green as seen at the end of in last trading. With action -9.17%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 20.19%, with the 5-day performance at -9.17% in the red. However, in the 30-day time frame, BridgeBio Pharma Inc (NASDAQ:BBIO) is 16.95% up. Looking at the short shares, we see there were 20.38 million shares sold at short interest cover period of 8.07 days.
The consensus price target for the stock as assigned by Wall Street analysts is 46, meaning bulls need an upside of 28.3% from its current market value. According to analyst projections, BBIO’s forecast low is 45 with 53 as the target high. To hit the forecast high, the stock’s price needs a -60.7% plunge from its current level, while the stock would need to soar -36.45% for it to hit the projected low.
BridgeBio Pharma Inc (BBIO) estimates and forecasts
Data shows that the BridgeBio Pharma Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 25.97% over the past 6 months, a 35.19% in annual growth rate that is considerably higher than the industry average of 27.40%. Year-over-year growth is forecast to reach 2,928.45% up from the last financial year.
Consensus estimates given by 13 financial analysts project the company’s revenue in the current quarter to hit an average of 4.01M. 7 analysts are of the opinion that BridgeBio Pharma Inc’s revenue for the current quarter will be 47.36M. The company’s revenue for the corresponding quarters a year ago was 1.75M and 211.12M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 129.81%. The estimates for the next quarter sales put growth at -77.57%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -13.29%. The 2025 estimates are for BridgeBio Pharma Inc earnings to increase by 36.14%, but the outlook for the next 5-year period is at 15.24% per year.
BBIO Dividends
BridgeBio Pharma Inc is expected to release its next quarterly earnings report in March.
BridgeBio Pharma Inc (NASDAQ:BBIO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.91% of BridgeBio Pharma Inc shares while 92.41% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 95.18%. There are 92.41% institutions holding the BridgeBio Pharma Inc stock share, with KOHLBERG KRAVIS ROBERTS & CO. L.P. the top institutional holder. As of 2024-06-30, the company held 16.5582% of the shares, roughly 31.06 million BBIO shares worth $786.77 million.
VIKING GLOBAL INVESTORS LP holds the second largest percentage of outstanding shares, with 13.3917% or 25.12 million shares worth $636.31 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 4.53 shares estimated at $149.46 million under it, the former controlled 2.40% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.08% of the shares, roughly 3.93 shares worth around $129.67 million.
